The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.

MLA

Butzkueven, Helmut, et al. “The CLARION Study Design and Status Update: A Long-Term, Registry-Based Study Evaluating Adverse Events of Special Interest in Patients with Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets.” Current Medical Research and Opinion, vol. 38, no. 7, July 2022, pp. 1167–76. EBSCOhost, https://doi.org/10.1080/03007995.2022.2059977.

APA

Butzkueven, H., Moore, N., Aydemir, A., Sõnajalg, J., Bezemer, I., Korhonen, P., & Sabidó, M. (2022). The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets. Current Medical Research and Opinion, 38(7), 1167–1176. https://doi.org/10.1080/03007995.2022.2059977

Chicago

Butzkueven, Helmut, Nicholas Moore, Aida Aydemir, Jaak Sõnajalg, Irene Bezemer, Pasi Korhonen, and Meritxell Sabidó. 2022. “The CLARION Study Design and Status Update: A Long-Term, Registry-Based Study Evaluating Adverse Events of Special Interest in Patients with Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets.” Current Medical Research and Opinion 38 (7): 1167–76. doi:10.1080/03007995.2022.2059977.